Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer Clinical Trial

Official title:

A Phase II Study of OSI-774 (NSC 718781) in Patients With Locally Advanced and/or Metastatic Carcinoma of the Endometrium

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00030485
• Other study ID #: I148
• Secondary ID: CAN-NCIC-IND148N
• Status: Completed
• Phase: Phase 2
• First received: February 14, 2002
• Last updated: January 24, 2014
• Start date: January 2002
• Est. completion date: April 2007

Study information

• Verified date: January 2011
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.

PURPOSE: Phase II trial to determine the effectiveness of erlotinib in treating patients who have locally advanced and/or metastatic endometrial cancer.

Description:

OBJECTIVES:

• Determine the efficacy of erlotinib, in terms of response rate and duration of stable disease, in patients with locally advanced and/or metastatic carcinoma of the endometrium.

• Determine the toxicity of this drug in these patients.

• Determine the time to progression and duration of response in patients treated with this drug.

• Correlate objective tumor response with levels of epidermal growth factor receptor expression in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed at 4 weeks. Patients with complete or partial response or stable disease are also followed every 3 months until relapse or death.

PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 12-18 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: April 2007
• Est. primary completion date: April 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed metastatic and/or locally advanced adenocarcinoma or adenosquamous carcinoma of the endometrium

• Incurable by standard therapies

• Clinically and/or radiologically documented disease with at least 1 unidimensionally measurable site

• At least 20 mm by x-ray, physical exam, or CT scan OR

• At least 10 mm by spiral CT scan

• Bone metastases considered nonmeasurable

• Tumor tissue from primary tumor available for assessing epidermal growth factor receptor (EGFR) status

• No uterine sarcomas (leiomyosarcoma), mixed mullerian tumors, and/or adenosarcomas

• No known brain metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• ECOG 0-2

Life expectancy:

• At least 12 weeks

Hematopoietic:

• Platelet count at least 100,000/mm3

• Absolute granulocyte count at least 1,500/mm3

Hepatic:

• Bilirubin no greater than upper limit of normal (ULN)

• AST/ALT no greater than 2.5 times ULN

Renal:

• Creatinine no greater than 1.5 times ULN

Cardiovascular:

• No symptomatic congestive heart failure

• No unstable angina

• No cardiac arrhythmia

Gastrointestinal:

• No gastrointestinal (GI) tract disease that would preclude ability to take oral medication

• No requirement for IV alimentation

• No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)

• No active peptic ulcer disease

Ophthalmic:

• No significant ophthalmologic abnormalities, including any of the following:

• Prior severe dry eye syndrome, Sjogren's syndrome, or keratoconjunctivitis sicca

• Severe-exposure keratopathy

• Disorders that would increase the risk of epithelium-related complications (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic keratitis)

• Congenital abnormality (e.g., Fuch's dystrophy)

• Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)

• Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)

• No concurrent ocular inflammation or infection

Other:

• No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix

• No prior allergic reaction attributed to compounds of similar biological or chemical composition to erlotinib

• No other concurrent serious illness or medical condition that would preclude study

• No prior significant neurologic or psychiatric disorder that would preclude study

• No active uncontrolled infection

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for endometrial cancer

Endocrine therapy:

• No more than 1 prior hormonal therapy (progestational agent or aromatase inhibitor) in the adjuvant or metastatic setting

• At least 1 week since prior hormonal therapy

Radiotherapy:

• At least 4 weeks since prior radiotherapy (except for low-dose palliative radiotherapy) and recovered

Surgery:

• At least 3 weeks since prior major surgery and recovered

• No prior surgical procedures affecting absorption

• No concurrent ophthalmic surgery

Other:

• No prior EGFR-targeting therapies

• No other concurrent investigational therapy

• No other concurrent anticancer therapy

• Concurrent oral anticoagulants (e.g., warfarin) allowed provided there is increased vigilance with respect to monitoring INR

• Concurrent low molecular weight heparin allowed at investigator's discretion

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• Endometrial Cancer

Intervention

Drug:
• erlotinib hydrochloride

Locations

Country	Name	City	State
Canada	Tom Baker Cancer Center - Calgary	Calgary	Alberta
Canada	Cross Cancer Institute	Edmonton	Alberta
Canada	Margaret and Charles Juravinski Cancer Centre	Hamilton	Ontario
Canada	Kingston Regional Cancer Centre	Kingston	Ontario
Canada	Cancer Care Ontario-London Regional Cancer Centre	London	Ontario
Canada	Hopital Notre- Dame du CHUM	Montreal	Quebec
Canada	Princess Margaret Hospital	Toronto	Ontario
Canada	British Columbia Cancer Agency	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)	Canadian Cancer Trials Group

Country where clinical trial is conducted

Canada, 

References & Publications (2)

Oza A, Elit L, Eisenhauer E, et al.: Phase II study of erlotinib (Tarceva, OSI 774) in women with recurrent or metastatic endometrial cancer -- NCIC IND.148. [Abstract] Clin Cancer Res 9 (Suppl): A-105, 6094s, 2003.

Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008 Se — View Citation